Literature DB >> 2917424

A properdin dependent nephritic factor slowly activating C3, C5, and C9 in membranoproliferative glomerulonephritis, types I and III.

C W Clardy1, J Forristal, C F Strife, C D West.   

Abstract

The IgG fraction of serum from patients with membranoproliferative glomerulonephritis (MPGN) types I and III was found to contain a nephritic factor (NFI/III) which differed from that usually present in MPGN type II and partial lipodystrophy (NFII) in that it converts C5 and C9 as well as C3, is dependent on properdin for its activity, and requires an incubation period of several hours rather than 30 min for its demonstration. C3 conversion occurred in the absence of an intact classical pathway. This nephritic factor was found in patients with reduced serum levels of terminal components and its activity, like that of the nephritic factor in MPGN type II, correlated with the serum C3 level indicating that these nephritic factors play a large role in producing hypocomplementemia. Although potentially nephritogenic because of its ability to activate the terminal pathway, the presence of this nephritic factor did not clearly correlate with clinical course.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2917424     DOI: 10.1016/0090-1229(89)90141-4

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  12 in total

Review 1.  Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.

Authors:  Marina Noris; Roberta Donadelli; Giuseppe Remuzzi
Journal:  Pediatr Nephrol       Date:  2018-06-09       Impact factor: 3.714

2.  Mesangiocapillary glomerulonephritis associated with meningococcal meningitis, C3 nephritic factor and persistently low complement C3 and C5.

Authors:  S A Hulton; R A Risdon; M J Dillon
Journal:  Pediatr Nephrol       Date:  1992-05       Impact factor: 3.714

3.  Occurrence of C3 nephritic factor and C4 nephritic factor in membranoproliferative glomerulonephritis (MPGN).

Authors:  H Ohi; T Yasugi
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

Review 4.  Idiopathic membranoproliferative glomerulonephritis in childhood.

Authors:  C D West
Journal:  Pediatr Nephrol       Date:  1992-01       Impact factor: 3.714

5.  Complement activation by whole endotoxin is blocked by a monoclonal antibody to factor B.

Authors:  C W Clardy
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

Review 6.  Properdin in complement activation and tissue injury.

Authors:  Allison M Lesher; Bo Nilsson; Wen-Chao Song
Journal:  Mol Immunol       Date:  2013-06-29       Impact factor: 4.407

7.  Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy.

Authors:  Marloes A H M Michels; Nicole C A J van de Kar; Ramon M van den Bos; Thea J A M van der Velden; Sanne A W van Kraaij; Sebastian A Sarlea; Valentina Gracchi; Michiel J S Oosterveld; Elena B Volokhina; Lambertus P W J van den Heuvel
Journal:  Front Immunol       Date:  2019-06-17       Impact factor: 7.561

8.  Loss of properdin exacerbates C3 glomerulopathy resulting from factor H deficiency.

Authors:  Marieta M Ruseva; Katherine A Vernon; Allison M Lesher; Wilhelm J Schwaeble; Youssif M Ali; Marina Botto; Terence Cook; Wenchao Song; Cordula M Stover; Matthew Caleb Pickering
Journal:  J Am Soc Nephrol       Date:  2012-11-26       Impact factor: 14.978

Review 9.  Dense deposit disease and C3 glomerulopathy.

Authors:  Thomas D Barbour; Matthew C Pickering; H Terence Cook
Journal:  Semin Nephrol       Date:  2013-11       Impact factor: 5.299

10.  Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.

Authors:  Roberta Donadelli; Patrizia Pulieri; Rossella Piras; Paraskevas Iatropoulos; Elisabetta Valoti; Ariela Benigni; Giuseppe Remuzzi; Marina Noris
Journal:  Front Immunol       Date:  2018-10-15       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.